abstract |
The invention relates to novel regimens for the treatment of inflammatory arthritis, for example, of patients with rheumatoid arthritis (RA), for example, patients with high-risk rheumatoid arthritis (RA), which employ a therapeutically effective amount. of an antagonist of lL-17, for example, of a molecule that binds to IL-17 (for example, of an antibody to IL-17, or of the antigen binding fragment thereof, for example, secukinumab), or of a molecule that binds to the lL-17 receptors (for example, of an antibody to lL-17, or of the antigen binding fragment thereof). |